Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Sandalore was being discussed as a potential hair loss treatment. Users suggested waiting for more information in the future.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

The conversation discusses a hair loss treatment called "nanoxidil," which is similar to minoxidil but with better absorption. Users are curious about its effectiveness for hair regrowth.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

The conversation discusses skepticism about AI's role in solving hair loss, with mentions of treatments like finasteride. Some users express hope that AI could aid research, while others doubt its effectiveness without medical testing.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Fake Nizoral shampoo was identified by its pink label, with users discussing the importance of sourcing it from reliable pharmacies to avoid harmful effects. Nizoral is used weekly for androgenetic alopecia (AGA) and is noted for its antifungal properties that help maintain scalp health.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

People are discussing the Regenera Activa stem cell treatment for hair loss, expressing interest and seeking feedback on its effectiveness. Some are considering traveling to Singapore for the procedure, which costs £2000 in the UK.

A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.

A user experienced a dry, scaly scalp two weeks after microneedling with a dermapen at 1mm and applying Rogaine foam. They tried moisturizers and coconut oil without success and are seeking advice.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

Pilose antler extracts may promote hair growth in androgenetic alopecia by activating hair follicle stem cells through the AKT and Wnt pathways. However, results in mice may not directly apply to humans due to differences in genetic and biochemical conditions.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation discusses using 2-deoxy-D-ribose for hair loss treatment, with OP sharing positive results after a year of use. OP applied a simple formulation twice daily, without using finasteride or minoxidil.

The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

The conversation discusses hair regrowth progress using copper peptides and NAD+ without finasteride or minoxidil. Users suggest comparing wet and dry hair photos for better assessment.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.